Abbott splits into two units: Diversified Medical Products and Research-Based Pharmaceuticals

In a surprising release from Abbott Park (IL, USA) on October 19th (Wednesday) it was announced that Abbott will split up into two publically traded companies. While one unit will take care of its diversified medical products the other unit will be responsible for Abbott’s diversified medical products.

According to Miles D. White, the chairman and CEO of Abbott, this news is a significant event for Abbott and will reflect another dynamic change in Abbott’s 123 years history. This will ensure strengthened outlook and sustainable growth and shareholder returns, he said.

Abbott splits into two units: Portfolios of two companies


Features


Research-based pharma company


Diversified medical products company


New name


To be named

 

Abbott

 

Roles

 


Immunology, Multiple Sclerosis, Chronic kidney disease, Hepatitis C, Women’s health and oncology,    biologics and more

 

Medical products

 

 

Growth drivers

 


The company’s sustainable portfolio & advancing pipeline, including established biologics expertise

 

The company will generate nearly40 % of its sales in high-growth emerging markets, with further expansion expected in the coming years

 

Annual Sales
(2011 est.)


Nearly $18 Billion

 

 

Nearly $22 Billion

 

 

Portfolios

 

 


Humira, Lupron, Synagis, Zemplar, Kaletra, Creon, Duodopa, Synthroid, Androgel and others

 

 

Generics outside US, adult and pediatric nutritionals, core laboratory diagnostics, point of care and molecular diagnostics, and medical devices, including vascular devices, diabetes care, vision care and others

Source: [Abbott press release]

Recommended Posts